Wave Life Sciences, Inc. WVE
Wave Life Sciences, Inc. (Nasdaq: WVE) is a cardio-renal-metabolic drug developer. Its lead program, WVE-007, is in Phase 2 for Obesity. Its next catalyst on record is WVE-007: Phase 1 SAD 600mg cohort data (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: WVE-007 — Phase 1 SAD 600mg cohort data (Q4 2026). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| WVE-007 | Obesity | siRNA | Phase 2 |
| WVE-006 | Alpha-1 antitrypsin deficiency (AATD) | RNA editing oligonucleotide (AIMer) | Phase 2 |
| WVE-N531 | Duchenne muscular dystrophy (DMD), exon 53 skipping | oligonucleotide-other | Phase 1 |
| WVE-003 | Huntington's disease (HD) | oligonucleotide-other | Phase 1 |
| WVE-008 | PNPLA3 I148M liver disease | RNA editing oligonucleotide (AIMer) | Pre-clinical |
Recent results and decisions
- Oct 27, 2026n/a Planning underway for registrational trial of WVE-006 following positive FDA feedback on pathway for potential full and accelerated approval in AATD.
In October 2026, the company announced alignment with the U.S. Food and Drug Administration (FDA) on key aspects of its planned registrational pathway for WVE-006.
Filing - Oct 27, 2026n/a Wave expects to share data from the Phase 1 600 mg SAD cohort of WVE-007 in the fourth quarter of 2026.
Wave expects to share data from the Phase 1 600 mg SAD cohort in the fourth quarter of 2026.
Filing - Oct 27, 2026started Wave remains on track to initiate a clinical trial of WVE-007 as maintenance therapy following incretin discontinuation in the fourth quarter of 2026.
Wave remains on track to initiate a clinical trial of WVE-007 as a maintenance therapy to preserve weight loss following discontinuation of incretin treatment in the fourth quarter of 2026.
Filing
6 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.